Fig. 6: Inhibition of SRC and BRAFV600E reduces tumor growth in BRAFm CRC in vivo CDX models.
From: Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
a HT29 CDX models after treatment with single agent SRCi dasatinib, BRAF inhibitor vemurafenib or their combinations with SRC inhibitor (n = 6 mice per group, except NT (n = 7)). b HT29 CDX models after treatment with single agent SRCi dasatinib, BRAF inhibitor encorafenib or their combinations with SRC inhibitor (n = 7 mice per group; except, E + D (n = 6)). c BRAFm CRC PDX #1 treated with vehicle (VEH, control, n = 9), vemurafenib (n = 7), dasatinib (n = 7), vemurafenib and dasatinib (n = 8). d PDX #2 treated with vehicle (VEH, control, n = 6), encorafenib (n = 5), dasatinib (n = 5), cetuximab (n = 4), encorafenib and cetuximab (n = 6), encorafenib and dasatinib (n = 7), and the triplet combination of encorafenib, cetuximab and dasatinib (n = 7). Graphs represent: tumor volumes determined at indicated time points after treatments and last day tumor weight. Image of one representative tumor for each group after finishing the treatment were also shown. Data are represented as the mean ± SEM. Significance was considered for *P < 0.05, *P < 0.01 and **P < 0.001. NT non-treated, VEH vehicle, V vemurafenib, E encorafenib, D dasatinib, C cetuximab.
